Top Markets
#1 Status Status +20.04%
#2 FGRS (Figure Tokenized Stock) FGRS (Figure Tokenized Stock) +18.47%
#3 Ontology Gas Ontology Gas +12.46%
#4 GoPlus Security GoPlus Security +12.16%
#5 DMT-NAT DMT-NAT +9.70%
#6 Fake World Assets Fake World Assets +8.34%
#7 Provenance Blockchain Provenance Blockchain +6.75%
#8 Bedrock Bedrock +6.48%
#9 Janction Janction +6.24%
#10 Ontology Ontology +5.54%
Coin of the day
Status Status
設定
言語
日本
通貨
USD
テーマ
Cadrenal Therapeutics, Inc. Common Stock Cadrenal Therapeutics, Inc. Common Stock

Cadrenal Therapeutics, Inc. Common Stock

CVKD
株式のランク #33959
Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise... Cadrenal Therapeutics, Inc. operates as a biopharmaceutical enterprise primarily engaged in clinical development. The company's core focus is the advancement of Tecarfarin, a novel therapeutic agent that has received orphan drug designation. This treatment is engineered to prevent systemic thromboembolism originating from cardiac issues in patients suffering from both end-stage renal disease and atrial fibrillation. Established in 2022, the firm is headquartered in Ponte Vedra, Florida.
株価
$1.83
最終同期: 2026-08-14
時価総額
$6.53M
変化（1日）
-1.61%
変化（1年）
-85.57%
国
US
取引 Cadrenal Therapeutics, Inc. Common Stock (CVKD)

カテゴリー

Healthcare
Cadrenal Therapeutics, Inc. Common Stock（CVKD）のP/B比率
2026 時点のP/B比率 TTM: 0
Cadrenal Therapeutics, Inc. Common Stock の最新の財務報告および株価によると、現在のP/B比率（TTM）は 0 です。2026 年末時点でのP/B比率は 0 でした。
Cadrenal Therapeutics, Inc. Common Stock の P/B 比率の履歴（2026 ～ 2026）
各年末時点のP/B比率
年 P/B比率 変化
提供された日付のデータは十分ではありません。
同業他社のP/B比率
企業 P/B比率 P/B比率の差 国
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
 6.3419 -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
 6.2413 -
NL
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
 - -
CH
Samsung Biologics Co.,Ltd. Samsung Biologics Co.,Ltd.
Samsung Biologics Co.,Ltd.
207940.KS
 - -
KR
UCB S.A. UCB S.A.
UCB S.A.
UCB.BR
 3.4612 -
BE